Palazestrant not checked
Olema Oncology, Inc. · OP-1250
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”In the company’s words, NCT06016738 on ClinicalTrials.gov
- Tested for
- Breast Cancer (4 trials), Metastatic Breast Cancer (4 trials), ER Positive Breast Cancer (2 trials), HER2 Negative Breast Carcinoma (2 trials), Locally Advanced Breast Cancer (2 trials), Advanced Breast Cancer, Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and 5 more
- Main trialPhase 3
- “This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.”In the company’s words, NCT06016738 on ClinicalTrials.gov
- Other names
- OP-1250
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up3
- 30 May 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Oct 2026 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | |
| Phase 3Recruiting | Dec 2028 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | |
| Phase 1Active, not recruiting | Mar 2026 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | |
| Phase 1Recruiting | 30 May 2027 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | |
| Phase 1Active, not recruiting | 31 Dec 2027 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | |
| Phase 1/2Completed | 30 Jul 2024 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026